Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beauty Health (SKIN) Depreciation & Amortization (CF) (2020 - 2025)

Beauty Health (SKIN) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $637000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 79.15% to $637000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $4.7 million, a 63.67% decrease, with the full-year FY2024 number at $9.9 million, down 12.28% from a year prior.
  • Depreciation & Amortization (CF) was $637000.0 for Q3 2025 at Beauty Health, down from $711000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $4.3 million in Q4 2023 to a low of $637000.0 in Q3 2025.
  • A 5-year average of $1.9 million and a median of $1.9 million in 2025 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 709.45% in 2021, then plummeted 79.15% in 2025.
  • Beauty Health's Depreciation & Amortization (CF) stood at $2.0 million in 2021, then dropped by 7.11% to $1.9 million in 2022, then soared by 128.81% to $4.3 million in 2023, then plummeted by 66.47% to $1.5 million in 2024, then plummeted by 56.19% to $637000.0 in 2025.
  • Per Business Quant, the three most recent readings for SKIN's Depreciation & Amortization (CF) are $637000.0 (Q3 2025), $711000.0 (Q2 2025), and $1.9 million (Q1 2025).